 |
|
|
| |
Evaluation of Relative Bioavailability and Food Effect
of a Fixed-Dose Combination Tablet of Islatravir and Lenacapavir
|
| |
| |
IDWeek, October 19-22 2025, Atlanta, Georgia, USA
Jing Niu1, Haeyoung Zhang1, John Ling1, Sharline Madera1, Nerissa Kwok1, Steve West1, Diane Longo2, Gillian Gillespie2, Cyril Llamoso2, Dhananjay Marathe1
1Gilead Sciences, Inc., Foster City, CA, USA. 2Merck & Co., Inc., Rahway, NJ, USA.
EACS2025: Oral Weekly Islatravir Plus Lenacapavir in Virologically Suppressed People with HIV-1: 96 Week Outcomes from a Phase 2 Study - (10/20/25)
|
| |
|
|
|
|
|
